HOME >> BIOLOGY >> NEWS
Embryos that implant in uterus 'late' prove more likely to die in first weeks of pregnancy

Researchers at the National Institute of Environmental Health Sciences said today that fertilized human eggs that implant late are less likely to survive.

The road to birth is a perilous one. These same NIEHS scientists showed in 1988 (New England Journal of Medicine, 319, pp 189-94) that 25 percent of fertilized eggs fail to survive six weeks -- so early that most mothers did not know they had been pregnant. Only daily urine testing for shifting traces of a hormone called hCG confirmed these pregnancies and their loss. The 25 percent early loss, when added to the clinical miscarriages that occur later, means that at least one-third of all embryos fail.

Today, the researchers reported they have found that the lost fetuses tend to be those that implant late. (NEJM, June 10.) The implantation of the fertilized egg in the wall of the uterus is necessary for the nourishment and growth of the fetus. Surviving pregnancies implanted only about one day earlier, on average, than the non-survivors: 10.5 days v. 9.1 days from fertilization to implantation. But the day-by-day trend was clear. If a fertilized egg implanted by the ninth day, it had only a 13 percent chance of loss. The risk rose to 26 percent if the implantation was on the tenth day, 52 percent on the eleventh day, and 82 percent thereafter. All three implantations after day 12 ended in early loss. There was no association in the NIEHS study between late implantation and the clinical miscarriages that occurred later in pregnancy.

NIEHS' Allen J. Wilcox, M.D., Ph.D., Donna Baird, Ph.D., and Clarice R. Weinberg, Ph.D., said their study could not determine the mechanisms at work. They speculate that embryos that implant more slowly may be imperfect in some way. Thus, they said, "the uterus may be receptive to pregnancy only during a limited time-window, shutting out defective embryos that get there too late. This would spare a mother the physiologic burden of supp
'"/>

Contact: Bill Grigg
grigg@niehs.nih.gov
301-402-3378
NIH/National Institute of Environmental Health Sciences
10-Jun-1999


Page: 1 2

Related biology news :

1. First Dinosaur Embryo Skin Discovered -- Unhatched Embryos Are First Ever Found Of Giant-Plant Eating Dinosaurs
2. Who Needs Flowers? Transgenic Plants Sprout Embryos On Leaves
3. At Lifes Most Sensitive Stage, Embryos Cope With Stress
4. University of Pittsburgh medical center among first to implant heart assist device
5. Medical implants work better when you rough them up, study finds
6. DCI donor services begins distribution of tissue implants
7. Researchers model embryo implantation and tumour metastasis in fruit flies
8. Injectable tissue implant could repair ravages of breast cancer surgery
9. Improving bone implant technology
10. Researchers envision intelligent implants
11. Rutgers researchers test polymer reliability for medical implants

Post Your Comments:
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
(Date:4/16/2015)... 2015 /CNW/ - Bioenterprise Corporation is pleased to announce that ... Charlottetown , PEI.  Bioenterprise has established a ... Council for the commercialization of agricultural technologies and innovations. ... PEI ADAPT.  They have been at the heart of ... explains Dave Smardon , President & CEO of ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... Madison, NJ (PRWEB) April 16, 2015 ... recruited Dr. Joseph V. Gulfo to become the ... and Entrepreneurship. Simultaneously, FDU announced the kick-off of ... new program spearheaded by Dr. Gulfo, under the ... Silberman College of Business) and in collaboration with ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
Cached News: